Genitourinary Cancers | Clinical

October 19, 2021

Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.

October 19, 2021

An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.

October 19, 2021

Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.

October 19, 2021

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

October 19, 2021

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.

October 19, 2021

Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.

October 19, 2021

An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.

October 19, 2021

Dr Scott T. Tagawa reviews traditional imaging techniques and advances in imaging used in clinical practice for prostate cancer.

October 19, 2021

Scott T. Tagawa, MD, FACP, discusses the heterogeneity and features of prostate cancer and provides insight on biomarker testing.

October 19, 2021

Tomasz M. Beer, MD, FACP, shares unmet needs and clinical pearls for the management of patients with mCRPC.